The dawn of the New Year has brought with it a new lease of life for Organ transplant patients who have liver failure. For these patients the uphill struggle doesn't stop with finding a matching donor. In fact it would have just started.
Research has shown that despite all high tech matching done for liver transplant patients, organ rejection is still a common phenomenon. Transplant surgeon Ignazio Marino, M.D., of Thomas Jefferson University Hospital in Philadelphia, says that rejection happens in at least 40 percent of patients undergoing a liver transplant. A new medical breakthrough has shown that the combination of certain drugs has been able to reduce the chances of rejection among liver transplant.
AdvertisementDr. Marino and a team of researchers studied the effect of two anti-rejection drugs, Basiliximab and Tacrolimus. The medications were given to 50 liver transplant patients over a course of time.
"These two drugs, used in combination, allowed us to have a significant decrease in the rejection," Dr. Marino announced. "We went from about 40 percent rejection to only 12 percent."
Dr. Marino says this treatment is a sign of good things to come. "A transplant is not any longer a treatment to save a life momentarily. It is a treatment to give an excellent quality of life back to our patients."
Both drugs have been FDA approved and have minimal side affects.
PAndrogen Deprivation Therapy For Prostate Cancer Found To Increase The Risk Of Fractures Who Board To Discuss Asian Tsunami Related Health Issues M
You May Also Like